The proposed CPA platform utilizing CRISPR technology aims to address a significant unmet need in the rapid and accurate diagnosis of Bordetella infections, particularly pertussis. Given the ongoing outbreaks of whooping cough globally, this diagnostic tool could capture a substantial share of the infectious disease diagnostics market. However, the trial's withdrawal indicates potential challenges in establishing the platform as a lead unit, which may affect its commercial viability. Competitively, the platform would need to differentiate itself from existing diagnostic methods, such as PCR and serological tests, which currently dominate the market. Diligence should focus on the technological feasibility, regulatory pathways, and potential partnerships for further development.